Enochian Biosciences (ENOB) Stock Price, News & Analysis

Company Overview

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.40 to $0.79
• 52-Week Range: N/A
• Volume: 88,300 shs
• Average Volume: 137,347 shs
• Market Capitalization: $40.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ENOB Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Enochian Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enochian Biosciences investors own include Carnival (CCL), Ashford Hospitality Trust (AHT), Assertio (ASRT), Peabody Energy (BTU), PlayAGS (AGS), Alliance Resource Partners (ARLP) and Astronics (ATRO).

Company Calendar

• Today: 7/18/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ENOB
• CIK: 1527728
• Web: www.enochianbio.com
• Phone: (305) 918-1980
• Fax: N/A
• Employees: 22
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$113.43 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -154.69%
• Return on Assets: -130.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.33
• Quick Ratio: 0.33

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.37 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 58,280,000
• Free Float: 45,625,000
• Market Cap: $40.80 million
• Optionable: Not Optionable
• Beta: 1.09